USC study tests if mindfulness boosts psilocybin's mental health benefits

A clinical study at the University of Southern California is exploring the therapeutic potential of psilocybin. The research is funded by a grant from the Advanced Research Projects Agency for Health (ARPA-H) under the EVIDENT initiative. It aims to assess whether mindfulness meditation can boost the benefits of psilocybin-assisted therapy. The study involves around 72 middle-aged adults from Los Angeles. Participants are split into two groups: one receiving only psilocybin and the other receiving psilocybin combined with mindfulness training.

Researchers will use EEG, MRI/fMRI, biological samples, and psychological tests before and after treatment. Long-term follow-ups are planned at three, six, and twelve months to evaluate lasting effects. Psilocybin is already recognised by the FDA as a breakthrough therapy for major depressive disorder and treatment-resistant depression.

Dr. Rael Cahn and Dr. Caryn Lerman co-lead the project, which employs an open-label design for transparency. The team uses advanced neuroimaging and biological assays to analyse how psilocybin affects sensory processing, time perception, and self-referential thinking. These changes often lead to profound spiritual experiences. The findings could shape future psychedelic therapies. The study’s rigorous methods and long-term tracking may provide clear evidence of psilocybin’s durability and potential. The FDA’s existing designation highlights the drug’s promise in treating severe depression.